Legal advice: energy ratings
The buyers of my pharmacy have queried a rating of F on our energy performance certificate. What does this mean?
On any sale of the assets of a pharmacy business (i.e. any property and separate assets, but not a share sale) the seller has to produce to the buyer a standard energy performance certificate showing the energy rating of the property.
The grading works on a sliding scale basis with A+ being the most efficient and G the least efficient.
Minimum energy efficiency standards come into force on 1 April 2018, from when commercial premises (including pharmacies) for which an EPC is required can only be let out if they achieve an EPC rating of E or above unless:
- The premises are let for six months or for more than 99 years
- One of a list of exemptions apply:
- All cost effective improvement works that have a simple pay back period of seven years have been undertaken
- A landlord is unable to obtain a third party consent, for example, from the planning authority, lender, superior landlords or consent from a tenant under the lease to enter or carry out improvement works
- An independent surveyor determines that the energy efficiency improvements would devalue the property by more than five per cent (such as providing thermal insulation to the internal face of the external walls) or would damage the property.
These exemptions last for five years and to qualify a property owner must register the exemption that it is relying on.
Minimum energy efficiency standards will apply to continuing lettings from 1 April 2023 as well as new lettings, and the government has indicated that the minimum letting requirement for an EPC rating of E will be raised over time.
The introduction of these standards from next April will have a considerable impact on pharmacy property owners and occupiers if they want to let their premises, and action should be taken to comply.
This article was first published by P3 Pharmacy. This article was written by Claire Timmings. For more information please contact Claire at firstname.lastname@example.org or on +44 (0)1483 252 582
News & Insights
The menopause - can business afford to ignore the potential productivity loss of 14 million days a year?
It is clearly in the interests of business to retain the talent and experience of those working women who are dealing with the menopause.
Charles Russell Speechlys advises Kreos on growth capital investment in JenaValve Technologies, Inc.
Charles Russell Speechlys advised Kreos on its growth capital investment in a biotech company, JenaValve Technologies, Inc.
Charles Russell Speechlys advises Juno Health pharmacy group on its acquisition of the Avicenna Pharmacy group
Juno Health further establishes its position as one of the largest pharmacy chains in the Northeast of England.